Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease
Sponsor: Sumitomo Pharma America, Inc.
A PHASE3 clinical study on Chronic Bronchitis and Chronic Obstructive Pulmonary Disease, this trial is completed. The trial is conducted by Sumitomo Pharma America, Inc. and has accumulated 8 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sumitomo Pharma America, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Allentown, United States, Altoona, United States, Ann Arbor, United States, Austell, United States, Baltimore, United States, Bellingham, United States, Boston, United States, Butte, United States, Chapel Hill, United States, Charlotte, United States and 52 more location s